These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23159551)

  • 1. Sprint Fidelis lead fractures in patients with cardiac resynchronization therapy devices: insight from the Resynchronization/Defibrillation for Ambulatory Heart Failure (RAFT) study.
    Parkash R; Thibault B; Sterns L; Sapp J; Krahn A; Talajic M; Luce M; Yetisir E; Theoret-Patrick P; Wells G; Tang A
    Circulation; 2012 Dec; 126(25):2928-34. PubMed ID: 23159551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT).
    Healey JS; Hohnloser SH; Exner DV; Birnie DH; Parkash R; Connolly SJ; Krahn AD; Simpson CS; Thibault B; Basta M; Philippon F; Dorian P; Nair GM; Sivakumaran S; Yetisir E; Wells GA; Tang AS;
    Circ Heart Fail; 2012 Sep; 5(5):566-70. PubMed ID: 22896584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence, predictors, and procedural results of upgrade to resynchronization therapy: the RAFT upgrade substudy.
    Essebag V; Joza J; Birnie DH; Sapp JL; Sterns LD; Philippon F; Yee R; Crystal E; Kus T; Rinne C; Healey JS; Sami M; Thibault B; Exner DV; Coutu B; Simpson CS; Wulffhart Z; Yetisir E; Wells G; Tang AS
    Circ Arrhythm Electrophysiol; 2015 Feb; 8(1):152-8. PubMed ID: 25417892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cardiac resynchronization therapy on hospitalizations in the Resynchronization-Defibrillation for Ambulatory Heart Failure trial.
    Gillis AM; Kerr CR; Philippon F; Newton G; Talajic M; Froeschl M; Froeschl S; Swiggum E; Yetisir E; Wells GA; Tang AS
    Circulation; 2014 May; 129(20):2021-30. PubMed ID: 24610807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on small-diameter implantable cardioverter-defibrillator leads performance.
    van Rees JB; van Welsenes GH; Borleffs CJ; Thijssen J; van der Velde ET; van der Wall EE; van Erven L; Schalij MJ
    Pacing Clin Electrophysiol; 2012 Jun; 35(6):652-8. PubMed ID: 22352338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Battery longevity in cardiac resynchronization therapy implantable cardioverter defibrillators.
    Alam MB; Munir MB; Rattan R; Flanigan S; Adelstein E; Jain S; Saba S
    Europace; 2014 Feb; 16(2):246-51. PubMed ID: 24099864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Sprint Fidelis defibrillator lead failure is highly dependent on age.
    Girerd N; Nonin E; Pinot J; Morel E; Flys C; Scridon A; Chevalier P
    Arch Cardiovasc Dis; 2011; 104(6-7):388-95. PubMed ID: 21798471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cardiac resynchronization therapy and implantable cardioverter defibrillator on quality of life in patients with heart failure: a meta-analysis.
    Chen S; Yin Y; Krucoff MW
    Europace; 2012 Nov; 14(11):1602-7. PubMed ID: 23104857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular lead location and the risk of ventricular arrhythmias in the MADIT-CRT trial.
    Kutyifa V; Zareba W; McNitt S; Singh J; Hall WJ; Polonsky S; Goldenberg I; Huang DT; Merkely B; Wang PJ; Moss AJ; Klein H
    Eur Heart J; 2013 Jan; 34(3):184-90. PubMed ID: 23053173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left ventricular mechanical assist devices and cardiac device interactions: an observational case series.
    Foo D; Walker BD; Kuchar DL; Thorburn CW; Tay A; Hayward CS; Macdonald P; Keogh A; Kotlyar E; Spratt P; Jansz P
    Pacing Clin Electrophysiol; 2009 Jul; 32(7):879-87. PubMed ID: 19572863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality reduction of cardiac resynchronization and implantable cardioverter-defibrillator therapy in heart failure: an updated meta-analysis. Does recent evidence change the standard of care?
    Bertoldi EG; Polanczyk CA; Cunha V; Ziegelmann PK; Beck-da-Silva L; Rohde LE
    J Card Fail; 2011 Oct; 17(10):860-6. PubMed ID: 21962425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of functional Sprint Fidelis leads at cardiac resynchronization therapy-defibrillator generator replacement: a novel option for preventing inappropriate shocks from lead failure in fragile patients with high risk of sudden death.
    Zhu DWX; Chu MM; House CM
    Europace; 2017 Dec; 19(12):2007-2014. PubMed ID: 27940933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac resynchronization therapy reduces the risk of cardiac events in patients with diabetes enrolled in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT).
    Martin DT; McNitt S; Nesto RW; Rutter MK; Moss AJ
    Circ Heart Fail; 2011 May; 4(3):332-8. PubMed ID: 21350054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for implantable defibrillator lead fracture in a recalled and a nonrecalled lead.
    Morrison TB; Rea RF; Hodge DO; Crusan D; Koestler C; Asirvatham SJ; Bradley D; Shen WK; Munger TM; Hammill SC; Friedman PA
    J Cardiovasc Electrophysiol; 2010 Jun; 21(6):671-7. PubMed ID: 20082653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical predictors of Fidelis lead failure: report from the Canadian Heart Rhythm Society Device Committee.
    Birnie DH; Parkash R; Exner DV; Essebag V; Healey JS; Verma A; Coutu B; Kus T; Mangat I; Ayala-Paredes F; Nery P; Wells G; Krahn AD
    Circulation; 2012 Mar; 125(10):1217-25. PubMed ID: 22311781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter-defibrillator patients who are upgraded and respond to cardiac resynchronization therapy have less ventricular arrhythmias compared with nonresponders.
    Thijssen J; Borleffs CJ; Delgado V; van Rees JB; Mooyaart EA; van Bommel RJ; van Erven L; Boersma E; Bax JJ; Schalij MJ
    J Am Coll Cardiol; 2011 Nov; 58(22):2282-9. PubMed ID: 22093504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of upgrade to cardiac resynchronization therapy on ventricular arrhythmia frequency in patients with implantable cardioverter-defibrillators.
    Ermis C; Seutter R; Zhu AX; Benditt LC; VanHeel L; Sakaguchi S; Lurie KG; Lu F; Benditt DG
    J Am Coll Cardiol; 2005 Dec; 46(12):2258-63. PubMed ID: 16360055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact, safety, and efficacy of single- versus dual-coil ICD leads in MADIT-CRT.
    Kutyifa V; Huth Ruwald AC; Aktas MK; Jons C; McNitt S; Polonsky B; Geller L; Merkely B; Moss AJ; Zareba W; Bloch Thomsen PE
    J Cardiovasc Electrophysiol; 2013 Nov; 24(11):1246-52. PubMed ID: 23889863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ventricular tachycardia or ventricular fibrillation occurs less often in patients with left bundle branch block and combined resynchronization and defibrillators than in patients with narrow QRS and conventional defibrillators.
    Blaschke F; Knaus T; Celebi O; Krebs A; Nitardy A; Habedank D; Dietz R; Stockburger M
    Europace; 2012 Feb; 14(2):224-9. PubMed ID: 21946820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implantable cardioverter-defibrillator lead failure in children and young adults: a matter of lead diameter or lead design?
    Janson CM; Patel AR; Bonney WJ; Smoots K; Shah MJ
    J Am Coll Cardiol; 2014 Jan; 63(2):133-40. PubMed ID: 24140671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.